ENTA

Enanta Pharmaceuticals Inc

1 day chart

About ENTA

Enanta Pharmaceuticals, Inc. is a biotechnology company. The Company is engaged in development of small molecule drugs for the treatment of viral infections and liver diseases. The Company has clinical candidates for the disease targets, including respiratory syncytial virus (RSV), hepatitis B virus (HBV) and non-alcoholic steatohepatitis (NASH). The Company has discovered glecaprevir, a protease inhibitor discovered and developed for the treatment of chronic hepatitis C virus (HCV). Glecaprevir is co-formulated direct-acting antiviral (DAA), a combination treatment for HCV infection under the tradenames: MAVYRET and MAVIRET. Its product candidates also include EDP-514, EDP-305 and EDP-938. The Company's subsidiary is Enanta Pharmaceuticals Security Corporation.

Buy US stocks in Australia with $0 brokerage and trade ENTA today!

Market Capitalisation

$1.11B

Price-earnings ratio

Dividend yield

0.00%

Volume

High today

$54.20

Low today

$52.18

Open price

$0.00

52-week high

$102.00

52-week low

$37.59

Related Stocks

This does not constitute financial advice. You should do your own research before making an investment decision. Past performance is not a reliable indication of future performance. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.